JAN 09, 2018 4:38 PM PST

Viruses could inspire nano drug-delivery device

Researchers have discovered a path toward virus-like, nanoscale devices that may be able to deliver drugs to cells by chipping away at a viral protein.

The protein is one of three that make up the protective shell, called the capsid, of natural adeno-associated viruses (AAV). By making progressively smaller versions of the protein, the researchers made capsids with unique abilities and learned a great deal about AAV’s mechanisms.

Bioengineer Junghae Suh, an associate professor of bioengineering at Rice University, studies the manipulation of nondisease-causing AAVs to deliver helpful cargo like chemotherapy drugs. Her research has led to the development of viruses that scientists can trigger with light or by extracellular proteases associated with certain diseases.

AAVs are small—about 25 nanometers—and contain a single strand of DNA inside tough capsids that consist of a mosaic of proteins known as VP1, VP2, and VP3.

AAVs have been used to deliver gene-therapy payloads, but nobody has figured out how AAV capsids physically reconfigure themselves when triggered by external stimuli, Suh says. That was the starting point for her lab.

‘Biocomputing nanoparticles’

“This virus has intrinsic peptide (small protein) domains hidden inside the capsid,” she says. “When the virus infects a cell, it senses the low pH and other endosomal factors, and these peptide domains pop out onto the surface of the virus capsid.

“This conformational change, which we termed an ‘activatable peptide display,’ is important for the virus because the externalized domains break down the endosomal membrane and allow the virus to escape into the cytoplasm,” Suh says. “In addition, nuclear localization sequences in those domains allow the virus to transit into the nucleus. We believed we could replace that functionality with something else.”

Suh and lead author Nicole Thadani, a graduate student at Rice, think their mutant AAVs can become “biocomputing nanoparticles” that detect and process environmental inputs and produce controllable outputs. Modifying the capsid is the first step.

Of the three natural capsid proteins, only VP1 and VP2 can be triggered to expose their functional peptides, but neither can make a capsid on its own. Shorter VP3s can form capsids by themselves, but do not display peptides. In natural AAVs, VP3 proteins outnumber each of their compadres 10-to-1.

That limits the number of peptides that can be exposed, so Suh, Thadani and their coauthors set out to change the ratio. That led them to truncate VP2 and synthesize mosaic capsids with VP3, resulting in successful alteration of the number of exposed peptides.

Never before seen in nature

Based on previous research, they inserted a common hexahistidine tag that made it easy to monitor the surface display of the peptide region.

“We wanted to boost the protein’s activable property beyond what occurs in the native virus capsid,” Thadani says. “Rather than displaying just five copies of the peptide per capsid, now we may be able to display 20 or 30 and get more of the bioactivity that we want.”

They then made a truncated VP2 able to form a capsid on its own. “The results were quite surprising, and not obvious to us,” Suh says.

“We chopped down that VP2 component enough to form what we call a homomeric capsid, where the entire capsid is made up of just that mutant subunit. That gave us viruses that appear to have peptide ‘brushes’ that are always on the surface,” says Suh.

“A viral structure like that has never been seen in nature,” she explains. “We got a particle with this peptide brush, with loose ends everywhere. Now we want to know if we can use these loose ends to attach other things or carry out other functions.”

Homomeric AAVs display as many as 60 peptides, while researchers could reprogram mosaic AAVs to respond to stimuli specific to particular cells or tissues and display a smaller desired number of peptides, they say.

“Viruses have evolved to invade cells very effectively,” Suh says. “We want to use our virus as a nanoparticle platform to deliver protein- or peptide-based therapeutics more efficiently into cells. We want to harness what nature has already created, tweak it a little bit, and use it for our purposes.”

 

This article was originally posted on futurity.org

About the Author
  • The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists-including two Nobel laureates-work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
You May Also Like
AUG 24, 2020
Immunology
Injectable Drug Stops HIV From Entering Cells
AUG 24, 2020
Injectable Drug Stops HIV From Entering Cells
Once in the body, HIV tracks down T cells that bear the CD4 receptor. It attaches to these immune cells, fusing itself w ...
SEP 03, 2020
Drug Discovery & Development
Combination of Cholesterol Lowering Drugs Effective in Reducing Heart Disease
SEP 03, 2020
Combination of Cholesterol Lowering Drugs Effective in Reducing Heart Disease
A recent European study found that individuals taking a combination of lipid-lowering therapeutics may reduce the risk o ...
SEP 11, 2020
Drug Discovery & Development
Novel Therapeutic for ALS
SEP 11, 2020
Novel Therapeutic for ALS
The TDP-43 protein is a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). A ...
SEP 16, 2020
Drug Discovery & Development
Generic Cholesterol-Lowering Drugs Save Money
SEP 16, 2020
Generic Cholesterol-Lowering Drugs Save Money
Generic Cholesterol Drugs Are Saving Money Between 2014 to 2018, there has been a switch from brand name to generic chol ...
OCT 12, 2020
Drug Discovery & Development
Researchers Solve Key Problem for Cancer Immunotherapy
OCT 12, 2020
Researchers Solve Key Problem for Cancer Immunotherapy
Cancer immunotherapies are becoming increasingly promising as a standard-of-care treatment. However, despite their promi ...
OCT 29, 2020
Cardiology
Treating Cardiovascular Calcification at the Source
OCT 29, 2020
Treating Cardiovascular Calcification at the Source
The term cardiovascular disease covers a broad array of health problems. Everyone tends to think of heart attacks or hyp ...
Loading Comments...